Lee's Pharmaceutical | 李氏大藥廠

Corporate Spirit:

Science, our belief and aspiration

Mission:

Commit to R&D of innovative products to address unmet medical needs and to improve patients’ quality of life.

Core Values:

Innovation, Excellence and Resilience.

Vision:

Create win-win among patients, corporations and society.

Culture:

 

Direct, Plain, Pragmatic, Efficient.

A research-driven and market-oriented biopharmaceutical company with more than 25 years of operation in the pharmaceutical industry in China.

Manufacturing Sites

Self-owned manufacturing sites in Hefei, Anhui and Nansha, Guangzhou, China.

News & Media

09/12/2022
Dr. LI Xiao Yi Benjamin, the Founder of Lee’s Pharm was interviewed by Mediazone Group during “Most Valuable Companies in Hong Kong 2022 Awards” Ceremony
Hong Kong, November 30, 2022, the Most Valuable Companies in Hong Kong (HKMVC) 2022 Awards Ceremony organized by Mediazone Group, a reputable international business magazine publisher was successfully held at the Royal Pacific Hotel, Tsim Sha Tsui. Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) was honoured with the HKMVC 2022 award with the title of “Most Innovative Pharmaceutical Company”, in recognition of its extensive research and development experience and solid infrastructures. Dr. LI Xiaoyi Benjamin, the Founder and Director of Lee’s Pharm was invited to attend the ceremony and receive the award. Interview session was featured in the ceremony, giving insight into the achievements and latest development of winning companies. According to Dr. Li, Lee’s Pharm has launched various products in this year, such as the in-licensed products, Teglutik® and INOmax®, which help patients suffering from rare disease. To date, the Group has more than 40 products in its pipeline from early- to late-stage development. More products are expected to be launched in 2023, such as an oncology product treating cervical cancer. Lee’s Pharm focuses on China, Hong Kong and Taiwan market, and is expanding its business to Southeast Asia in 2023 by providing innovative pharmaceutical products, especially in the field of rare disease. Please click on the video below to watch the full interview.
Hong Kong, November 30, 2022, the Most Valuable Companies in Hong Kong (HKMVC) 2022 Awards Ceremony organized by Mediazone Group, a reputable international business magazine publisher was successfully held at the Royal Pacific Hotel, Tsim Sha Tsui. Lee’s Pharmaceutical Holdings Limited (“Lee’s...

Careers at Lee’s Pharm.

We strive continually to attract and retain talented professionals who share our values.
join us
join us

Corporate Spirit:

Science, our belief and aspiration

Mission:

Commit to R&D of innovative products to address unmet medical needs and to improve patients’ quality of life.

Core Values:

Innovation, Excellence and Resilience.

Vision:

Create win-win among patients, corporations and society.

Culture:

 

Direct, Plain, Pragmatic, Efficient.

News & Media

09/12/2022
Dr. LI Xiao Yi Benjamin, the Founder of Lee’s Pharm was interviewed by Mediazone Group during “Most Valuable Companies in Hong Kong 2022 Awards” Ceremony
Hong Kong, November 30, 2022, the Most Valuable Companies in Hong Kong (HKMVC) 2022 Awards Ceremony organized by Mediazone Group, a reputable international business magazine publisher was successfully held at the Royal Pacific Hotel, Tsim Sha Tsui. Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) was honoured with the HKMVC 2022 award with the title of “Most Innovative Pharmaceutical Company”, in recognition of its extensive research and development experience and solid infrastructures. Dr. LI Xiaoyi Benjamin, the Founder and Director of Lee’s Pharm was invited to attend the ceremony and receive the award. Interview session was featured in the ceremony, giving insight into the achievements and latest development of winning companies. According to Dr. Li, Lee’s Pharm has launched various products in this year, such as the in-licensed products, Teglutik® and INOmax®, which help patients suffering from rare disease. To date, the Group has more than 40 products in its pipeline from early- to late-stage development. More products are expected to be launched in 2023, such as an oncology product treating cervical cancer. Lee’s Pharm focuses on China, Hong Kong and Taiwan market, and is expanding its business to Southeast Asia in 2023 by providing innovative pharmaceutical products, especially in the field of rare disease. Please click on the video below to watch the full interview.
Hong Kong, November 30, 2022, the Most Valuable Companies in Hong Kong (HKMVC) 2022 Awards Ceremony organized by Mediazone Group, a reputable international business magazine publisher was successfully held at the Royal Pacific Hotel, Tsim Sha Tsui. Lee’s Pharmaceutical Holdings Limited (“Lee’s...
know more
know more